NewsJagsonpal Pharmaceuticals Independent Director Mrs. Pallavi Dinodia Gupta Resigns Effective May 18, 2026Jagsonpal Pharmaceuticals Independent Director Mrs. Pallavi Dinodia Gupta Resigns Effective May 18, 2026
Mrs. Pallavi Dinodia Gupta (DIN- 06566637) has resigned as Independent Director of Jagsonpal Pharmaceuticals Limited with effect from May 18, 2026, citing professional commitments, personal engagements, and health considerations. She will also cease to be a member of the Audit Committee and Corporate Social Responsibility Committee, and will step down as Chairperson of the Stakeholders Relationship Committee. The resignation was disclosed pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. Mrs. Gupta confirmed that no other material reasons exist beyond those stated in her resignation letter.
*this image is generated using AI for illustrative purposes only.
Jagsonpal Pharmaceuticals Limited has informed the stock exchanges of the resignation of Mrs. Pallavi Dinodia Gupta (DIN- 06566637) from the position of Independent Director of the company, with effect from May 18, 2026. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the Listing Regulations.
Resignation Details
The company intimated the exchanges on May 18, 2026, as required under SEBI's updated master circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The key details of the resignation are summarised below:
| Parameter: | Details |
|---|---|
| Name of Director: | Mrs. Pallavi Dinodia Gupta |
| DIN: | 06566637 |
| Designation: | Independent Director |
| Effective Date of Resignation: | May 18, 2026 |
| Reason for Resignation: | Personal and professional reasons |
Impact on Board Committees
Consequent to her resignation, Mrs. Pallavi Dinodia Gupta will also cease to hold her positions across multiple board-level committees of Jagsonpal Pharmaceuticals. The committee roles she will vacate are as follows:
- Audit Committee: Member
- Corporate Social Responsibility Committee: Member
- Stakeholders Relationship Committee: Chairperson
Directorships in Other Listed Entities
As part of the mandatory disclosure under Regulation 30, the company also provided details of Mrs. Gupta's directorships and committee memberships in other listed entities at the time of her resignation:
| Listed Entity: | Category of Directorship | Committee Memberships |
|---|---|---|
| IndiaMART InterMESH Limited: | Independent Director | Member – Audit Committee, Stakeholder Relationship Committee, Corporate Social Responsibility & Sustainability Committee; Chairman – Nomination & Remuneration Committee, Committee of Independent Directors |
| Voith Paper Fabrics India Limited: | Independent Director | Member – Nomination & Remuneration Committee; Chairperson – Audit Committee |
| Lumax Industries Limited: | Independent Director | Member – Audit Committee, Corporate Social Responsibility Committee |
Reasons Cited by the Resigning Director
In her resignation letter addressed to the Board of Directors of Jagsonpal Pharmaceuticals Limited, Mrs. Pallavi Dinodia Gupta cited increasing professional commitments, certain personal engagements, and health considerations as the primary reasons for her decision. She stated that these factors constrained her ability to devote the requisite time and attention to effectively discharge her duties and responsibilities as an Independent Director to the standards she considered appropriate.
Mrs. Gupta confirmed that there are no other material reasons for her resignation beyond those stated in her resignation letter, in compliance with applicable regulatory requirements. The company's Company Secretary and Compliance Officer, Pratham Rawal, signed and submitted the regulatory filing on May 18, 2026.
Historical Stock Returns for Jagsonpal Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.12% | -2.84% | -3.98% | -7.23% | -14.79% | +294.05% |
How will Jagsonpal Pharmaceuticals ensure continuity and compliance in its Audit and Stakeholders Relationship Committees while searching for a replacement Independent Director?
Given SEBI's regulatory requirements on minimum board composition, what is the timeline within which Jagsonpal Pharmaceuticals must appoint a new Independent Director to avoid non-compliance penalties?
Could Mrs. Gupta's simultaneous resignation from Jagsonpal while retaining directorships at IndiaMART, Voith Paper, and Lumax signal a strategic consolidation of her board commitments, and how might this affect those companies?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
